MX2022001743A - Formas en estado solido de (s)-2-(((s)-6,8-difluor-1,2,3,4-tetrahi dronaftalen-2-il)amino)-n-(1-(2-metil-1-(neopentilamino)propan-2- il)-1h-imidazol-4-il)pentanamida y usos de la misma. - Google Patents

Formas en estado solido de (s)-2-(((s)-6,8-difluor-1,2,3,4-tetrahi dronaftalen-2-il)amino)-n-(1-(2-metil-1-(neopentilamino)propan-2- il)-1h-imidazol-4-il)pentanamida y usos de la misma.

Info

Publication number
MX2022001743A
MX2022001743A MX2022001743A MX2022001743A MX2022001743A MX 2022001743 A MX2022001743 A MX 2022001743A MX 2022001743 A MX2022001743 A MX 2022001743A MX 2022001743 A MX2022001743 A MX 2022001743A MX 2022001743 A MX2022001743 A MX 2022001743A
Authority
MX
Mexico
Prior art keywords
solid state
state forms
aphthalen
tetrahydron
neopentylamino
Prior art date
Application number
MX2022001743A
Other languages
English (en)
Inventor
Elaine Greer
Stephen Anderson
Mark Maloney
Shu Yu
Ekaterina Albert
Emily Rigsbee
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of MX2022001743A publication Critical patent/MX2022001743A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/88—Nitrogen atoms, e.g. allantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/417—Imidazole-alkylamines, e.g. histamine, phentolamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente divulgación se relaciona con: a) formas en estado sólido de las sales bromhidrato del Compuesto 1; b) composiciones farmacéuticas que comprenden una o más formas en estado sólido de las sales bromhidrato del Compuesto 1, y, opcionalmente, un portador farmacéuticamente aceptable; c) métodos de tratamiento de tumores o de cánceres por medio de la administración de una o más formas en estado sólido de las sales bromhidrato del Compuesto 1 a un sujeto en necesidad de ello; y d) métodos para la preparación de las formas en estado sólido del Compuesto 1.
MX2022001743A 2019-08-09 2019-08-09 Formas en estado solido de (s)-2-(((s)-6,8-difluor-1,2,3,4-tetrahi dronaftalen-2-il)amino)-n-(1-(2-metil-1-(neopentilamino)propan-2- il)-1h-imidazol-4-il)pentanamida y usos de la misma. MX2022001743A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2019/045948 WO2021029854A1 (en) 2019-08-09 2019-08-09 Solid state forms of (s)-2-(((s)-6,8-difluoro-1,2,3,4-tetrahydronaphthalen-2-yl)amino)-n-(1-(2-methyl-1-(neopentylamino)propan-2-yl)-1h-imidazol-4-yl)pentanamide and uses thereof

Publications (1)

Publication Number Publication Date
MX2022001743A true MX2022001743A (es) 2022-05-10

Family

ID=67734850

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022001743A MX2022001743A (es) 2019-08-09 2019-08-09 Formas en estado solido de (s)-2-(((s)-6,8-difluor-1,2,3,4-tetrahi dronaftalen-2-il)amino)-n-(1-(2-metil-1-(neopentilamino)propan-2- il)-1h-imidazol-4-il)pentanamida y usos de la misma.

Country Status (13)

Country Link
EP (1) EP4010322A1 (es)
JP (1) JP2022553479A (es)
KR (1) KR20220062510A (es)
CN (1) CN114555562A (es)
AR (1) AR119614A1 (es)
AU (1) AU2019461090A1 (es)
BR (1) BR112022002392A2 (es)
CA (1) CA3150424A1 (es)
CO (1) CO2022002731A2 (es)
IL (1) IL290428A (es)
MX (1) MX2022001743A (es)
PE (1) PE20221252A1 (es)
WO (1) WO2021029854A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112022018251A2 (pt) * 2020-03-13 2022-11-08 Springworks Therapeutics Inc Terapia de combinação com nirogacestat e terapia dirigida a bcma e usos da mesma
US11504354B1 (en) * 2021-09-08 2022-11-22 SpringWorks Therapeutics Inc.. Chlorinated tetralin compounds and pharmaceutical compositions
CN118302412A (zh) 2021-11-23 2024-07-05 梯瓦制药国际有限责任公司 Nirogacestat盐的固态形式
WO2023174390A1 (zh) * 2022-03-17 2023-09-21 苏州科睿思制药有限公司 尼罗司他二氢溴酸盐的晶型及其制备方法和用途

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA011689B1 (ru) * 2004-03-23 2009-04-28 Пфайзер Продактс Инк. Имидазольные соединения для лечения нейродегенеративных расстройств
WO2018045273A2 (en) * 2016-09-02 2018-03-08 The Brigham And Women's Hospital, Inc. Compositions and methods for treating neoplasias
WO2019053727A1 (en) * 2017-09-18 2019-03-21 Ramot At Tel-Aviv University Ltd. REDIFFERENCING IN VITRO DEVELOPED CELLS FROM HUMAN PANCREATIC ISLAND BEA CELLS ADULPTED BY SMALL MOLECULE INHIBITORS OF THE SIGNALING PATH

Also Published As

Publication number Publication date
WO2021029854A1 (en) 2021-02-18
EP4010322A1 (en) 2022-06-15
IL290428A (en) 2022-07-01
CO2022002731A2 (es) 2022-05-20
AU2019461090A1 (en) 2022-03-17
AR119614A1 (es) 2021-12-29
PE20221252A1 (es) 2022-08-16
CN114555562A (zh) 2022-05-27
BR112022002392A2 (pt) 2022-04-26
JP2022553479A (ja) 2022-12-23
KR20220062510A (ko) 2022-05-17
CA3150424A1 (en) 2021-02-18

Similar Documents

Publication Publication Date Title
ZA202202325B (en) Solid state forms of (s)-2-(((s)-6,8-difluoro-1,2,3,4-tetrahydronaphthalen-2-yl)amino)-n-(1-(2-methyl-1-(neopentylamino)propan-2-yl)-1h-imidazol-4-yl)pentanamide and uses thereof
MX2022001743A (es) Formas en estado solido de (s)-2-(((s)-6,8-difluor-1,2,3,4-tetrahi dronaftalen-2-il)amino)-n-(1-(2-metil-1-(neopentilamino)propan-2- il)-1h-imidazol-4-il)pentanamida y usos de la misma.
MX2021000887A (es) Compuestos espiroheterociclicos y metodos de uso de los mismos para el tratamiento de cancer.
MX2019013954A (es) Inhibidores covalentes de kras.
MX2022005053A (es) Inhibidores de peque?as moleculas de mutante g12c de kras.
MX2021005924A (es) Compuestos y metodos de uso de los mismos para el tratamiento del cancer.
PH12020552004A1 (en) Heterocyclic compounds as kinase inhibitors, compositions comprising the heterocyclic compound, and methods of use thereof
MX2023007192A (es) Inhibidores de prmt5.
MX2022006865A (es) Tetrahidrofuranos sustituidos como moduladores de canales de sodio.
MX2022015272A (es) Inhibidores de la proteina kras g12c y usos de estos.
MX2016012365A (es) Combinaciones.
MX2010006799A (es) Benzofuropirimidinonas como inhibidores de la proteina cinasa.
NZ700761A (en) Salt form of a human histone methyltransferase ezh2 inhibitor
MX2021010106A (es) Inhibidores de la via de respuesta al estres integrada.
PH12021551256A1 (en) Pantetheine derivatives and uses thereof
MX2013010770A (es) Tratamiento de tumores solidos.
WO2016133903A3 (en) Combination therapy for cancer treatment
MX2023009222A (es) Inhibidores tricíclicos-amido-bicíclicos de prmt5.
MX2018005715A (es) Uso de antagonistas del receptor ep4 para el tratamiento de cancer de higado asociado con nash.
SA520411787B1 (ar) مشتقات بنزيميدازول واستخداماتها
MX2022015629A (es) Uso de vibegron para tratar vejiga sobreactiva.
WO2018027084A3 (en) Combination of glucagon receptor antagonists and pi3k pathway inhibitors for the treatment of cancer
MX2020007152A (es) Compuestos heterociclicos sustituidos con amina como inhibidores de ehmt2, sales de los mismos, y metodos de sintesis de los mismos.
MX2020005771A (es) Composicion y metodo para tratar el linfoma periferico de linfocitos t y el linfoma cutaneo de linfocitos t.
PH12021550878A1 (en) Cyclodextrin-based formulation of a bcl-2 inhibitor